Correction of Psoriatic T Cell Signatures by Deucravacitinib
ConditionPsoriasis Vulgaris
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-75
SponsorUniversity of California, San Francisco
About this trial
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
18 years of age or older
Patients with moderate-severe psoriasis (BSA >= 10%, PASI >=12, static Physician's Global Assessment (sPGA) 3 and above)
Disqualifiers
taking systemic immunosuppressives in the last 12 weeks
pregnancy
severe immunodeficiency (either from genetic or infectious causes).
tuberculosis or other active serious infection
Trial design
Design model
Single group
Treatments tested in this trial
deucravacitinib
DrugTreatment with deucravacitinib, skin biopsy and blood analysis pre- and mid-treatment
Treatment groups
25 Participants
are divided into 1 treatment groupGroup A: deucravacitinib treatmentExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Change in Psoriasis Area and Severity Index (PASI) score
Change in severity and extent of psoriasis (calculated by Psoriasis Area and Severity Index (PASI) score); scale range of 0 to 72, 72 being maximal disease
Time frame
pre-treatment, 4 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
University of California, San Francisco
Lead sponsor
Bristol-Myers Squibb
Collaborator
Source ClinicalTrials.gov